Drugs Brain and Behavior (DDP)

Overview

In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.

Full Title of Study: “Drugs Brain and Behavior”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 1, 2024

Interventions

  • Drug: Methamphetamine
    • Participants will be given 20 mg of Methamphetamine.
  • Drug: placebo oral tablet
    • Participants will be given a placebo capsule that will only contain lactose.

Arms, Groups and Cohorts

  • Experimental: Placebo Then Methamphetamine
    • Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 72 hours later and will receive 20 mg methamphetamine.
  • Experimental: MethamphetamineThen Placebo
    • Participants first receive 20 mg methamphetamine at their first session in the laboratory Then will return to the laboratory 72 hours later and will receive placebo.

Clinical Trial Outcome Measures

Primary Measures

  • Change in SUbjective Effects as Assessed by Score on “Feel Drug”, “Feel High”, “Like Drug”, and “Want More” Sub-scales of Drug Effects Questionnaire (DEQ).
    • Time Frame: Time Frame: Day 1(baseline), 3
    • Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: “Feel Drug”, “Feel High”, “Like Drug”, and “Want More”. All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.

Participating in This Clinical Trial

Inclusion Criteria

  • BMI between 19 and 26 – Right Handed – Less than 4 alcohol or caffeinated beverages a day. Exclusion Criteria:

  • High blood pressure – Any medical condition requiring regular medication – Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis – Individuals with a history of dependence on stimulant drugs – Women who are pregnant or trying to become pregnant.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 35 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Chicago
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Harriet de Wit, Principal Investigator, Principal Investigator
  • Overall Contact(s)
    • Matthew Bona, 773-702-3560, dewitlab@yoda.bsd.uchicago.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.